<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518557</url>
  </required_header>
  <id_info>
    <org_study_id>SIMCERE-123456</org_study_id>
    <nct_id>NCT00518557</nct_id>
  </id_info>
  <brief_title>Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis</brief_title>
  <acronym>TACE HCC</acronym>
  <official_title>Combination Treatment of TACE With Recombinant Human Endostatin Administrated Via Hepatic Artery in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety and potential therapeutic benefits for
      patients with hepatocellular carcinoma by transcatheter chemoembolization with the
      recombinant endostatin (commercially available in China)which is also administrated via the
      hepatic artery. The hypothesis of this protocol is that TACE with antiangiogenic treatment
      may inhibit the proangiogenic effects induced by the hypoxia of TACE.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, Mortality</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients of this arm are treated by TACE together with Andostatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter Arterial Chemoembolization</intervention_name>
    <description>The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>TAE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cytologically or histologically documented HCC, who are candidates for
             TACE

          -  Child-Pugh Child A or B

          -  Age &gt;= 18

          -  Measurable disease by RECIST criteria;

          -  Performance status ECOG 0-2

          -  Previous local therapy completed &gt; 4 weeks

          -  Written informed consent signed

          -  Normal organ and marrow function defined as:

        Haematopoietic:

          -  WBC ≥ 3,000/µlplatelet count &gt; 80,000/mm3

          -  haemoglobin &gt; 9g/dL

          -  Hepatic: Albumin ≥ 2.8 g/dl.serum total bilirubin ≤ 3 mg/dl; AST or ALT &lt; 5 x ULN

          -  Renal: creatinine &lt; 1.5 x ULN

        Exclusion Criteria:

          -  Metastases

          -  Prior or concomitant chemotherapy or radiation therapy

          -  VEGF/VEGFR- inhibitors or other anti-angiogenesis agents

          -  Severe and/or uncontrolled medical conditions:

          -  Congestive heart failure, serious cardiac arrhythmia, active coronary artery

          -  Severe renal impairment

          -  Patients who anticipate receiving major surgery during the course of the

          -  Pregnant or breastfeeding patients

          -  Evidence of bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao-Jun Teng, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda Hospital, Southeast University, Nanjing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Hui Chen, MD</last_name>
    <phone>+86 25 83272121</phone>
    <email>noriko0706@sohu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gang Deng, MD, Ph.D</last_name>
    <phone>+86 25 83272118</phone>
    <email>dmm1996@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Interventional Radiology, Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Hui Chen, MD</last_name>
      <phone>+86 25 83272121</phone>
      <email>noriko0706@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>Gang Deng, MD</last_name>
      <phone>+86 25 83272118</phone>
      <email>dmm1996@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gang Deng, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shi-Cheng He, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin-He Guo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov</url>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <keyword>liver cancer</keyword>
  <keyword>interventional radiology</keyword>
  <keyword>Chemoembolization</keyword>
  <keyword>Safety</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

